Accurate Diagnosis, Prognosis and Treatment for Cancer Patients

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of cancer patients.  Leveraging the advancements generated by the Human Genome Project and a cutting edge genomics platform for tumor gene expression profiling, Agendia’s tests are designed to help physicians more accurately individualize cancer therapy. Agendia currently markets four products around the world, with several new genomic tests in development, and was the first to successfully achieve FDA clearance under the new IVDMIA guidance.

With MammaPrint^®, you and your patients have an FDA-cleared test that can help deliver more personalized treatment. MammaPrint provides you with an accurate assessment of your patients’ true risk of breast cancer metastases, thereby aiding you in determining the need for adjuvant chemotherapy. With TargetPrint^®, you receive accurate quantitative results of Estrogen Receptor, Progesterone Receptor and HER2 gene expression levels, adding to traditional clinico-pathologic findings and allowing more informed prognosis and treatment decisions.

Agendia performs testing at its state-of-the-art CLIA (Clinical Laboratory Improvement Act) and CAP (College of American Pathologists) registered and compliant genomics laboratories in Irvine, California and Amsterdam, The Netherlands.

For more information on how Agendia’s products and services can assist you, please read further within this website.  To speak with an Agendia representative, please feel free to contact us at Agendia Customer Care or provide your contact information and we will gladly assist you.